PT UBC Medical Indonesia Tbk (IDX:LABS)
Indonesia · Delayed Price · Currency is IDR 163.00
0.00 (0.00%)
Sep 2, 2026, 2:15 PM WIB
IDX:LABS Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 207,821 | 199,295 | 147,637 | 136,699 | 93,292 | 129,960 | |
Revenue Growth | 22.39% | 34.99% | 8.00% | 46.53% | -28.21% | - |
Cost of Revenue | 122,720 | 120,097 | 90,882 | 82,135 | 56,136 | 80,529 |
Gross Profit | 85,101 | 79,198 | 56,755 | 54,564 | 37,156 | 49,431 |
Selling, General & Admin | 63,638 | 58,052 | 47,412 | 48,558 | 36,033 | 43,743 |
Operating Expenses | 64,418 | 58,832 | 47,803 | 48,720 | 33,758 | 46,240 |
Operating Income | 20,683 | 20,366 | 8,952 | 5,844 | 3,398 | 3,191 |
Interest Expense | -1,212 | -1,246 | -3,041 | -2,153 | -1,554 | -112.31 |
Interest & Investment Income | 214.87 | 299.31 | 212.16 | 1.95 | 23.74 | 63.25 |
Earnings From Equity Investments | - | - | - | - | 1,122 | - |
Currency Exchange Gain (Loss) | -3,876 | -1,275 | -1,289 | 501.88 | -1,203 | -906.66 |
Other Non Operating Income (Expenses) | -274.62 | 116.53 | 315.58 | 1,093 | -72.19 | 245.6 |
EBT Excluding Unusual Items | 15,536 | 18,261 | 5,150 | 5,287 | 1,713 | 2,481 |
Gain (Loss) on Sale of Investments | - | - | - | 882.29 | - | - |
Gain (Loss) on Sale of Assets | -830.78 | -738.75 | 139.93 | 61.82 | 2,814 | 201.48 |
Pretax Income | 14,705 | 17,522 | 5,290 | 6,231 | 4,528 | 2,682 |
Income Tax Expense | 4,015 | 4,015 | 2,337 | 4,041 | 1,693 | 2,374 |
Earnings From Continuing Operations | 10,690 | 13,507 | 2,952 | 2,190 | 2,834 | 308.25 |
Minority Interest in Earnings | 0.03 | 0.04 | -0.02 | 0.02 | 0 | - |
Net Income | 10,690 | 13,507 | 2,952 | 2,190 | 2,834 | 308.25 |
Net Income to Common | 10,690 | 13,507 | 2,952 | 2,190 | 2,834 | 308.25 |
Net Income Growth | 29.70% | 357.50% | 34.84% | -22.75% | 819.43% | - |
Shares Outstanding (Basic) | 3,950 | 3,950 | 3,950 | 2,354 | - | - |
Shares Outstanding (Diluted) | 3,950 | 3,950 | 3,950 | 2,354 | - | - |
Shares Change | - | - | 67.78% | - | - | - |
EPS (Basic) | 2.71 | 3.42 | 0.75 | 0.93 | - | - |
EPS (Diluted) | 2.71 | 3.42 | 0.75 | 0.93 | - | - |
EPS Growth | 29.70% | 357.50% | -19.63% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -4,558 | 8,681 | -20,490 | -34,233 | -18,327 | -32,341 |
Free Cash Flow Per Share | -1.15 | 2.20 | -5.19 | -14.54 | - | - |
Gross Margin | 40.95% | 39.74% | 38.44% | 39.91% | 39.83% | 38.04% |
Operating Margin | 9.95% | 10.22% | 6.06% | 4.28% | 3.64% | 2.46% |
Profit Margin | 5.14% | 6.78% | 2.00% | 1.60% | 3.04% | 0.24% |
Free Cash Flow Margin | -2.19% | 4.36% | -13.88% | -25.04% | -19.65% | -24.88% |
EBITDA | 32,170 | 33,007 | 21,114 | 15,402 | 12,187 | 11,009 |
EBITDA Margin | 15.48% | 16.56% | 14.30% | 11.27% | 13.06% | 8.47% |
D&A For EBITDA | 11,487 | 12,641 | 12,162 | 9,559 | 8,789 | 7,818 |
EBIT | 20,683 | 20,366 | 8,952 | 5,844 | 3,398 | 3,191 |
EBIT Margin | 9.95% | 10.22% | 6.06% | 4.28% | 3.64% | 2.46% |
Effective Tax Rate | 27.30% | 22.91% | 44.19% | 64.86% | 37.40% | 88.51% |
Advertising Expenses | - | 1,461 | 1,154 | 1,123 | 244.6 | 1,268 |